Novavax, Inc.
NVAXNASDAQHealthcare● Active
$8.80
$-0.69(-7.32%)
Market Cap$1.4B
P/E Ratio—
52W High$11.97
52W Low$6.13
Novavax, Inc. (NVAX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NVAX · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
-$0.06
Est. -$0.25 · +76.0%
Revenue
$0.14B
Est. $0.08B · +74.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 7-Quarter EPS Beat Streak
NVAX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$0.40 | — | — | — | $0.05B | — |
| ▲ Q2 FY2026 | May 6, 2026 | -$0.25 | -$0.06 | +76.0% | $0.14B | $0.08B | +74.8% |
| ▲ Q1 FY2026 | Feb 26, 2026 | -$0.66 | $0.11 | +116.7% | $0.15B | $0.09B | +63.8% |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$1.08 | -$0.62 | +42.6% | $0.07B | $0.09B | -21.9% |
| ▲ Q3 FY2025 | Aug 6, 2025 | -$0.07 | $0.62 | +985.7% | $0.24B | $0.06B | +330.1% |
| ▲ Q2 FY2025 | May 8, 2025 | $0.71 | $2.93 | +312.7% | $0.67B | $0.34B | +93.9% |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$0.75 | -$0.51 | +32.0% | $0.09B | $0.08B | +4.7% |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.87 | -$0.76 | +12.6% | $0.08B | $0.09B | -7.0% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$0.40
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Beat
EPS Actual
-$0.06
EPS Est.
-$0.25
EPS Surpr.
+76.0%
Revenue
$0.14B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
$0.11
EPS Est.
-$0.66
EPS Surpr.
+116.7%
Revenue
$0.15B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.62
EPS Est.
-$1.08
EPS Surpr.
+42.6%
Revenue
$0.07B
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
$0.62
EPS Est.
-$0.07
EPS Surpr.
+985.7%
Revenue
$0.24B
Q2 FY2025
May 8, 2025Beat
EPS Actual
$2.93
EPS Est.
$0.71
EPS Surpr.
+312.7%
Revenue
$0.67B
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
-$0.51
EPS Est.
-$0.75
EPS Surpr.
+32.0%
Revenue
$0.09B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.76
EPS Est.
-$0.87
EPS Surpr.
+12.6%
Revenue
$0.08B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.04 | $0.14 | $0.26 | 2 |
| Q3 FY2027 | $0.12 | $0.45 | $0.86 | 1 |
| Q2 FY2027 | $-0.43 | $-0.23 | $-0.06 | 1 |
| Q1 FY2027 | $-0.60 | $-0.32 | $-0.08 | 2 |
| Q4 FY2026 | $0.01 | $0.06 | $0.11 | 2 |
| Q3 FY2026 | $-1.69 | $-0.05 | $1.16 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.2B | 3 |
| Q3 FY2027 | $0.1B | $0.3B | $0.4B | 3 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2026 | $0.1B | $0.1B | $0.2B | 5 |
| Q3 FY2026 | $0.0B | $0.1B | $0.2B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 6, 2026 | +76.0% | $8.10 | $9.36 | +15.56% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +116.7% | $9.53 | $11.19 | +17.42% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +42.6% | $7.69 | $7.59 | -1.30% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +985.7% | $6.73 | $7.58 | +12.63% |
| ▲ Q2 FY2025 | May 8, 2025 | +312.7% | $5.95 | $6.66 | +11.93% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +32.0% | $7.32 | $7.06 | -3.55% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +12.6% | $9.01 | $8.46 | -6.10% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -39.6% | $10.71 | $11.68 | +9.06% |
Q2 FY2026+15.56%
Report Date
May 6, 2026
EPS Beat/Miss
+76.0%
Price Before
$8.10
Price After
$9.36
Q1 FY2026+17.42%
Report Date
Feb 26, 2026
EPS Beat/Miss
+116.7%
Price Before
$9.53
Price After
$11.19
Q4 FY2025-1.30%
Report Date
Nov 6, 2025
EPS Beat/Miss
+42.6%
Price Before
$7.69
Price After
$7.59
Q3 FY2025+12.63%
Report Date
Aug 6, 2025
EPS Beat/Miss
+985.7%
Price Before
$6.73
Price After
$7.58
Q2 FY2025+11.93%
Report Date
May 8, 2025
EPS Beat/Miss
+312.7%
Price Before
$5.95
Price After
$6.66
Q1 FY2025-3.55%
Report Date
Feb 27, 2025
EPS Beat/Miss
+32.0%
Price Before
$7.32
Price After
$7.06
Q4 FY2024-6.10%
Report Date
Nov 12, 2024
EPS Beat/Miss
+12.6%
Price Before
$9.01
Price After
$8.46
Q3 FY2024+9.06%
Report Date
Aug 8, 2024
EPS Beat/Miss
-39.6%
Price Before
$10.71
Price After
$11.68
Avg Beat Reaction+6.66%
Avg Miss Reaction+9.06%
Beat Rate7 / 8 quarters
Largest Move+17.42% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NVAX ends December
Novavax, Inc. (NVAX) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $-0.06 — beating the analyst consensus of $-0.25 by +76.0%. NVAX has beaten EPS estimates for 7 consecutive quarters. The next NVAX earnings date is expected around September 1, 2026.
Each quarter, investors track NVAX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NVAX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NVAX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NVAX earnings · 5 questionsNovavax, Inc.'s next earnings report is expected around September 1, 2026. NVAX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NVAX historically reports after market close (AMC).
NVAX earnings datewhen is NVAX earningsNVAX next earnings datewhen does NVAX report earningsNVAX earnings calendar
▸ Source: FMP · Novavax, Inc. SEC filings · US GAAP · Novavax, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026